A drug for resisting Marek's disease virus and application of taraxasterol or ferulic acid and their combined use in drug preparation
By using dandelion sterol and ferulic acid to inhibit the activity of MDV049 protease and US3 protein kinase, the problem that existing vaccines cannot prevent MDV replication is solved, effective inhibition and virulence control of Marek's disease virus is achieved, and vaccine defense effect is improved.
Patent Information
- Application Number
- CN202410247597.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-05
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-03-05
AI Technical Summary
The existing Marek's disease virus (MDV) vaccine cannot effectively prevent the virus from replication and virility in chickens, causing vaccine-immunized chickens to become new sources of infection and promote the emergence of more virulent strains, and lack of Effective drugs that inhibit MDV replication.
Dandelion sterol and ferulic acid were used alone or in combination as drugs to inhibit MDV replication, and by inhibiting the activity of MDV049 protease and US3 protein kinase, respectively, as protease inhibitors and kinase inhibitors, significantly reducing viral replication and preventing tumor formation.
Under safe doses, dandelion sterol and ferulic acid can effectively inhibit the replication of MDV, reduce the activity of viruses in chicken cells, prevent the occurrence of Marek's disease and enhance virility, improve the vaccine defense effect, and signal the chicken cell. and proteins have no significant inhibitory effect.
Smart Images

Figure CN118021824B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the application field of natural compounds, and in particular to the application of natural compounds taraxasterol and ferulic acid alone or in combination as drugs for inhibiting the replication of Marek's disease virus and resisting the occurrence of Marek's disease. Background Art
[0002] Chickens infected with the pathogenic serotype I Marek's disease virus (MDV) will cause Marek's disease (MD), which is a highly lethal viral infectious disease with multiple visceral tumors. Chickens are the most important natural host of MDV. MDV belongs to the cell-bound herpesvirus family, and its molecular structure and genetic composition are similar to those of alpha herpesviruses.
[0003] At present, the main means of defending against MD is to vaccinate against MD. Studies have shown that vaccination against MD can protect chickens from developing MD malignant tumors, but chickens immunized with MD vaccines can still be infected with MDV, and MD vaccines cannot prevent the replication, maturation, and release of MDV in chickens. Therefore, chickens immunized with MD vaccines become new sources of infection for MDV, and the immune pressure of the vaccine further promotes the continuous enhancement of MDV virulence, resulting in the emergence of more virulent MDV strains. Therefore, MDV is still an important threat to the poultry industry. However, preventing MDV from replicating in chicken cells is an effective way to curb the proliferation, spread, and virulence enhancement of MDV, and is also the key to controlling MD outbreaks and enhancing the defensive effect of vaccines.
[0004] Taraxasterol is also called taraxasterol. Its CAS number is 1059-14-9. Its English name is Taraxasterol. Its molecular formula is C 30 H 50 O, with a relative molecular mass of 426.72. Taraxasterol is a pentacyclic triterpenoid compound isolated from dandelion. Taraxasterol has good immunomodulatory and anti-inflammatory effects, but there has been no report on the effect of taraxasterol on Marek's disease or any inhibition of MDV virus replication and activity.
[0005] Other Chinese names for ferulic acid include ferulic acid, ferulic acid, ferulic acid, nano ferulic acid, etc. Its English name is Ferulic Acid, with a CAS number of 1135-24-6, a molecular formula of C10H10O4, and a molecular weight of 194.18. Ferulic acid is widely distributed in various plants and is widely used in food, medicine, cosmetics and other industries. Ferulic acid has been used clinically to scavenge free radicals, resist thrombosis, fight bacteria and inflammation, inhibit tumors, prevent and treat hypertension, heart disease, enhance sperm motility, and resist radiation damage. Ferulic acid has a significant inhibitory effect on cold virus (IV), respiratory syncytial virus (RSV) and human immunodeficiency virus (HIV) and has low toxicity. Ferulic acid is easily metabolized by the human body and can be used as a food preservative. It has a wide range of uses in food, medicine, etc. Ferulic acid plays a role in various cell life processes, but there has been no report on ferulic acid's anti-Marek's disease or any inhibition of MDV virus replication and activity. Summary of the invention
[0006] The present invention provides a new use of taraxasterol and ferulic acid alone or in combination as drugs for inhibiting MDV replication and resisting Marek's disease in chickens in order to resist the occurrence of chicken MD, inhibit the replication of MDV in chicken cells, improve the defense effect of MD vaccine and curb the enhancement of MDV toxicity. Based on the MDV049 protease and US3 protein kinase activity inhibition system encoded by MDV, as well as cell inoculation virus and Marek's disease animal models, it is screened that taraxasterol and ferulic acid alone or in combination can effectively inhibit the replication of MDV and the generation of tumors in virus-challenging experimental animal models at a safe dosage.
[0007] The present invention provides a drug for inhibiting MDV replication, including taraxasterol and ferulic acid used alone or in combination. The taraxasterol and ferulic acid used alone or in combination have the effect of resisting MDV and MD.
[0008] The drugs or other reagents used in the present invention are all mixtures of commercial reagents or artificially synthesized reagents. The preparation or extraction methods of the drugs, including taraxasterol, ferulic acid or other reagents used, are prior art contents and are not the subject of protection of the present invention.
[0009] Taraxacinol inhibits the activity of MDV049 protease encoded by MDV, and ferulic acid inhibits the activity of US3 protein kinase encoded by MDV. The functions of MDV049 protein and US3 have not been explained in detail. The present invention performs high-throughput screening on more than 5,000 compounds, and fortunately finds that the taraxacinol has the effect of inhibiting the activity of MDV049 protease, and ferulic acid has the effect of inhibiting the activity of US3 protein kinase. Through the research of the present invention, the taraxacinol inhibits MDV replication at the cellular level by inhibiting MDV049 protease and ferulic acid inhibits US3 protein kinase, while no significant inhibitory effect is produced on the signal pathway and protein of the chicken cell itself.
[0010] Taraxasterol as a protease inhibitor and ferulic acid as a protein kinase inhibitor can affect the functions of multiple signal pathways and proteins in cells. The research of the present invention shows that taraxasterol specifically inhibits the activity of MDV049 protease and ferulic acid specifically inhibits the activity of US3 protein kinase.
[0011] The invention provides a drug for inhibiting Marek's disease virus, comprising an MDV049 protease inhibitor and / or a US3 protein kinase inhibitor. The drug comprises taraxasterol or ferulic acid or taraxasterol and ferulic acid are used in combination.
[0012] Preferably, the drug is used to inhibit intracellular Marek's disease virus replication, and the concentration of taraxasterol at the cell level is 0.5-350 μM, or the concentration of ferulic acid at the cell level is 3-300 μM, or a combination of 0.5-350 μM taraxasterol and 3-300 μM ferulic acid. Preferably, within this combined drug concentration range, the molar concentration ratio of taraxasterol: ferulic acid can play a synergistic inhibitory effect on MDV replication under the conditions of 2:1-1:8, and further preferably, the inhibitory effect is best under the combined drug condition of 1:2. Preferably, within this combined drug concentration range, the molar concentration ratio of taraxasterol: ferulic acid is 2:1, 1:1, 1:4, 1:8.
[0013] By adding the taraxasterol and ferulic acid alone or in combination to the culture system of chicken cells infected with MDV, MDV replication is significantly inhibited. Preferably, the taraxasterol and ferulic acid inhibit viral replication at the level of CEF cells (chicken embryo fibroblasts) or DF-1 cells (chicken embryo fibroblast cell line) infected with MDV.
[0014] Any of the above items is preferably that the concentrations of taraxasterol and ferulic acid at the cellular level are 0.5-350 μM for taraxasterol and 3-300 μM for ferulic acid, respectively, and the combination within these concentration ranges. The cells at the cellular level are preferably CEF cells or DF-1 cells.
[0015] Any of the above is preferably that the concentration of taraxasterol at the cell level is preferably 0.5 to 350 μM, and further preferably, 0.5 μM taraxasterol inhibits the replication of MDV at the CEF cell level. Preferably, 0.5 μM, 2 μM, 5 μM, 10 μM, 50 μM, 100 μM, 200 μM, 350 μM and taraxasterol in the range therebetween effectively inhibit the replication of MDV in cells infected with MDV, and have no toxic side effects on the cells themselves. When the concentration of taraxasterol is greater than 0.5 μM, the replication of the virus can be significantly reduced. When the concentration reaches 5 μM, the replication of the virus in the cell and the infection of the cell can be basically completely inhibited, and the drug does not cause significant damage to the cell in this concentration range.
[0016] Any of the above is preferably that the concentration of the ferulic acid at the cell level is preferably 3 to 300 μM, and further preferably, 14 μM of ferulic acid inhibits the replication of MDV at the CEF cell level, preferably, 3 μM, 5 μM, 10 μM, 20 μM, 50 μM, 80 μM, 150 μM, 200 μM, 250 μM, 300 μM and the range of ferulic acid therebetween all effectively inhibit the replication of MDV in cells infected with MDV, and have no toxic side effects on the cells themselves. When the concentration of ferulic acid is greater than 3 μM, the replication of the virus can be significantly reduced. When the concentration reaches 10 μM, the replication of the virus in the cell and the infection of the cell can be basically completely inhibited, and the drug does not cause significant damage to the cell in this concentration range.
[0017] Any of the above items is preferably 0.5-350 μM taraxasterol and 3-300 μM ferulic acid used alone or in combination, preferably, taraxasterol and ferulic acid are used alone or in combination within the preferred range of any of the above items,
[0018] Preferably, any of the above items is that the MDV is serotype I MDV.
[0019] Any of the above items is preferably that the drug is used in animals, and the dosage used in animals is: 0.3-340 mg / (kg·d) of taraxasterol, or 3-400 mg / (kg·d) of ferulic acid, or a combination of 0.3-340 mg / (kg·d) of taraxasterol and 3-400 mg / (kg·d) of ferulic acid. Preferably, within the combined dosage range, the taraxasterol: ferulic acid dosage ratio can play a synergistic inhibition of MDV replication and anti-MD effect in animals under the conditions of 2:1-1:8, and further preferably, the inhibition effect is best under the combined dosage condition of 1:2. Preferably, within the combined dosage range, the taraxasterol: ferulic acid dosage ratio is 2:1, 1:1, 1:4, 1:8.
[0020] Preferably, any of the above items is administered by oral administration, intraperitoneal injection or intramuscular injection.
[0021] Any of the above items is preferably that the dosage of taraxasterol when taken orally is 20 to 340 mg / (kg·d), the dosage of taraxasterol when injected intraperitoneally is 0.3 to 150 mg / (kg·d), and the dosage of taraxasterol when injected intramuscularly is 2 to 240 mg / (kg·d); the dosage range of ferulic acid is: the dosage of ferulic acid when taken orally is 10 to 400 mg / (kg·d), the dosage of ferulic acid when injected intraperitoneally is 3 to 240 mg / (kg·d), and the dosage of ferulic acid when injected intramuscularly is 6 to 300 mg / (kg·d); within the dosage range of taraxasterol and the dosage range of ferulic acid, taraxasterol and ferulic acid are used alone or in combination.
[0022] The present invention also provides a drug for preventing or resisting Marek's disease, comprising any of the above-mentioned drugs for inhibiting MDV replication.
[0023] Preferably, the drug for preventing or resisting Marek's disease provided by the present invention, the taraxasterol and ferulic acid are used alone or in combination, the dosage of the taraxasterol in animals is 0.3-340 mg / (kg·d), and the dosage of ferulic acid in animals is 3-400 mg / (kg·d). The dosage in animals is the dosage used in chickens. The taraxasterol is used as an MDV049 protease inhibitor, and ferulic acid is used as a US3 protein kinase inhibitor. The present invention first discovered that the taraxasterol inhibits the activity of MDV049 protease in the Marek's disease animal model, but has no inhibitory effect on the protease in the chicken's body; ferulic acid inhibits the activity of US3 protein kinase in the Marek's disease animal model, and taraxasterol and ferulic acid have no toxic side effects on chickens. The dosage can inhibit the activities of MDV049 protease and US3 protein kinase, can significantly inhibit the occurrence of symptoms such as internal bleeding and tumors in chickens infected with MDV, and can inhibit the replication of MDV in chicken T cells, that is, inhibit the occurrence of Marek's disease in chickens.
[0024] Preferably, the dosage of taraxasterol in animals is not less than 0.3 mg / (kg·d), and the dosage of ferulic acid in animals is not less than 3 mg / (kg·d). When the dosage of taraxasterol is greater than 0.3 mg / (kg·d), and the dosage of ferulic acid is greater than 3 mg / (kg·d), either alone or in combination, the occurrence of symptoms such as internal bleeding and tumors in chickens infected with MDV can be significantly inhibited, and the replication of MDV in chicken T cells can be inhibited, that is, taraxasterol and ferulic acid can inhibit the occurrence of Marek's disease in chickens.
[0025] Preferably, any of the above items is administered by oral administration, intraperitoneal injection or intramuscular injection.
[0026] Any of the above is preferably that the taraxasterol, when taken orally, has a dosage of 20 to 340 mg / (kg·d), preferably, the best oral dosage of taraxasterol is 150 mg / (kg·d), and other preferred oral dosages of taraxasterol are 20, 40, 60, 80, 100, 150, 170, 200, 220, 230, 260, 300, 340 mg / (kg·d) and ranges therebetween; when intraperitoneally injected, the dosage of taraxasterol is 0.3 to 150 mg / (kg·d), preferably, the best intraperitoneal dosage of taraxasterol is 60 mg / (kg·d). d), other preferred intraperitoneal doses of taraxasterol are 0.3, 0.5, 1.5, 2.5, 5.0, 10, 25, 50, 70, 100, 150 mg / (kg·d) and ranges therebetween; when injected intramuscularly, the dose of taraxasterol is 2 to 240 mg / (kg·d), preferably, the best intramuscular dose of taraxasterol is 80 mg / (kg·d), and other preferred intramuscular doses of taraxasterol are 2, 5, 10, 19, 26, 38, 42, 72, 97, 113, 144, 184, 209, 220, 240 mg / (kg·d) and ranges therebetween.
[0027] Any of the above items is preferably that the ferulic acid, when taken orally, has a dosage of 10 to 400 mg / (kg·d), preferably, the best oral dosage of ferulic acid is 120 mg / (kg·d), and other preferred oral dosages of ferulic acid are 10, 20, 30, 40, 60, 80, 100, 150, 200, 250, 300, 400 mg / (kg·d) and ranges therebetween; when intraperitoneally injected, the dosage of ferulic acid is 3 to 240 mg / (kg·d), preferably, the best intraperitoneal injection dosage of ferulic acid is 40 mg / (kg·d. ·d), other preferred ferulic acid intraperitoneal injection doses are 3, 5, 10, 20, 40, 60, 80, 100, 150, 200, 240 mg / (kg·d) and ranges therebetween; when injected intramuscularly, the ferulic acid dose is 6 to 300 mg / (kg·d), preferably, the best intramuscular injection dose of ferulic acid is 60 mg / (kg·d), and other preferred intramuscular injection doses of ferulic acid are 6, 12, 30, 40, 50, 60, 80, 100, 150, 200, 250, 300 mg / (kg·d) and ranges therebetween.
[0028] Any of the above items is preferably a combination of taraxasterol and ferulic acid within these dosage ranges. Preferably, 0.3-340 mg / (kg·d) of taraxasterol and 3-400 mg / (kg·d) of ferulic acid are used in combination in animals. Preferably, when taken orally, 20 to 340 mg / (kg·d) of taraxasterol and 10 to 400 mg / (kg·d) of ferulic acid are used in combination, and more preferably 20, 40, 60, 80, 100, 150, 170, 200, 220, 230, 260, 300, 340 mg / (kg·d) of taraxasterol and 10, 20, 30, 40, 60, 80, 100, 120, 150, 200, 250, 300, 400 mg / (kg·d) of ferulic acid and the like are taken orally. Preferably, 0.3 to 150 mg / (kg·d) of taraxasterol and 3 to 240 mg / (kg·d) of ferulic acid are used in combination by intraperitoneal injection, and more preferably, 0.3, 0.5, 1.5, 2.5, 5.0, 10, 25, 50, 60, 70, 100, 150 mg / (kg·d) and ranges therebetween of taraxasterol and 3, 5, 10, 20, 40, 60, 80, 100, 150, 200, 240 mg / (kg·d) and ranges therebetween of ferulic acid are used in combination by intraperitoneal injection. Preferably, during intramuscular injection, 2 to 240 mg / (kg·d) of taraxasterol and 6 to 300 mg / (kg·d) of ferulic acid are used in combination, and 2, 5, 10, 19, 26, 38, 42, 72, 80, 97, 113, 144, 184, 209, 220, 240 mg / (kg·d) and ranges therebetween of taraxasterol and 6, 12, 30, 40, 50, 60, 80, 100, 150, 200, 250, 300 mg / (kg·d) and ranges therebetween are used in combination by intramuscular injection.
[0029] Any of the above items is preferred, wherein the taraxasterol and ferulic acid are used alone or in combination within the dosage range of any of the above items to inhibit the formation of MD tumors in chickens infected with MDV.
[0030] The present invention also provides the use of taraxasterol in inhibiting the activity of MDV049 protease.
[0031] The invention also provides application of ferulic acid in inhibiting the activity of US3 protein kinase.
[0032] The present invention also provides the use of taraxasterol or ferulic acid or the combination of taraxasterol and ferulic acid in the preparation of medicine for preventing or treating Marek's disease.
[0033] The present invention also provides the use of taraxasterol or ferulic acid or the combination of taraxasterol and ferulic acid in the preparation of medicine for inhibiting tumor formation in chickens suffering from Marek's disease.
[0034] The present invention also provides the use of taraxasterol or ferulic acid or the combination of taraxasterol and ferulic acid in the preparation of a medicine for inhibiting the replication of Marek's disease virus in an in vivo or in vitro culture system. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 This is the result of taraxasterol in the preferred embodiment 1 of the present invention inhibiting the activity of MDV049 protease encoded by MDV.
[0036] Figure 2 This is the result of ferulic acid in preferred Example 2 of the present invention inhibiting the activity of US3 protein kinase encoded by MDV.
[0037] Figure 3 These are the results of the cytotoxicity of taraxasterol and ferulic acid alone or in combination on CEF cells according to the preferred embodiment 3 of the present invention.
[0038] Figure 4 This is a diagram of cytopathic effect (CPE) after three days of treatment with MDV or MDV+drug according to Example 3 of the present invention.
[0039] Figure 5 This is a graph showing the relationship between the concentrations of taraxasterol and ferulic acid and the CPE area of MDV in Experimental Example 3 of the present invention.
[0040] Figure 6 This is a graph showing the relationship between the MDV genome copy number in CEF cells of Example 3 of the present invention and the single and combined use of taraxasterol and ferulic acid.
[0041] Figure 7 This is a graph showing the relationship between the MDV genome copy number in the MD model chicken T cells of Example 4 of the present invention and the use of taraxasterol and ferulic acid alone or in combination.
[0042] Figure 8 This is a relationship diagram between the incidence of MD in MD model chickens in Example 4 of the present invention and the use of taraxasterol and ferulic acid alone or in combination.
[0043] Fig. 9 This is a schematic diagram of the relationship between the single medication and combined medication of taraxasterol and ferulic acid in Example 4 of the present invention and the number of tumors in MD model chickens. DETAILED DESCRIPTION
[0044] The present invention is described more clearly and completely through the following examples, but the examples described are only part of the embodiments of the present invention, not all of them. The embodiments are to help understand the present invention and should not be used to limit the scope of protection of the present invention.
[0045] Example 1
[0046] Taraxasterol inhibits the activity of MDV049 protease encoded by MDV.
[0047] Enzyme reaction system: A 100 μL reaction system contains 2.5 nM MDV049 protease (Genbank#AAG14229.1, preparation and activity analysis methods refer to: Wang Mengyun (mentor: Ai Yongxing). Activity and enzymatic specificity analysis of MDV-encoded deubiquitinase UL36 (Thesis) (2017).), 1× reaction buffer (50 mM HEPES pH7.8, 0.1 mg / mL BSA, 0.5 mM EDTA, 1 mM DTT), 70 nM fluorescent substrate Ub-Rho110 is added to the reaction, incubated at 37°C, and the fluorescence intensity change is measured on a fluorescence spectrophotometer to obtain the initial reaction rate. The reaction system with different concentrations of taraxasterol added was used as the inhibitor group "taraxasterol group", and the reaction system without drug but with an equal amount of PBS added was used as the "control group". The results are as follows Figure 1 In the "control group", MDV049 protease hydrolyzed Ub-Rho110 normally with a good initial reaction rate, while the activity of MDV049 in the different concentrations of taraxasterol groups was inhibited and the initial reaction rate decreased. This result shows that taraxasterol inhibits the enzymatic activity of MDV049 encoded by MDV.
[0048] Example 2
[0049] Ferulic acid inhibits US3 protein kinase activity
[0050] Enzymatic reaction system: containing 1×HEPES reaction buffer (50mM HEPES, 150mM NaCl, 5mM MgCl2, 5mM DTT, 50μM ATP pH8.0), 2μg substrate HA-chHDAC1, 0.5μg US3 protein kinase (GenBank#AAG14266.1, enzyme preparation and activity analysis reference: Liao, Y; Lupiani, B; Ai-Mahmood, M, et al.; Marek's disease virus US3 protein kinase phosphorylates chicken HDAC 1and 2and regulates viral replication and pathogenesis, 2021, PLoS Pathog, 17: e1009307.), add water to 30μL, react at 37℃ for 30min, the reaction products were separated by SDS-PAGE gel, and HA primary antibody and anti-mouse monoclonal antibody were used as secondary antibodies for standard Western blotting. The phosphorylated HA-chHDAC1 content was detected by blot to determine the activity of US3 protein kinase. The group without ferulic acid was the "control group", and the reaction system with ferulic acid added under the same conditions was the "ferulic acid group". Figure 2 Compared with the control group, the phosphorylated HA-chHDAC1 content of the reaction product decreased significantly in the different concentrations of the "ferulic acid group". This result indicates that ferulic acid inhibits the activity of the US3 protein kinase encoded by MDV.
[0051] Example 3
[0052] Preparation of CEF cells and infection with MDV:
[0053] 1. Take a 10-day-old SPF chicken embryo and wipe it with alcohol cotton, starting from the air chamber and wiping around to disinfect. Then put the chicken embryo into the clean bench with the air chamber facing upwards. Carefully use autoclaved tweezers to break the air chamber and remove the eggshell.
[0054] 2. Use new sterile tweezers to peel off the chorioallantoic membrane, discard the egg shell and vitelline membrane. Use sterile tweezers to clamp the head of the chicken embryo and gently move it to the plate.
[0055] 3. Fix the head with sterile tweezers, cut off the head, limbs, and organs with sterile scissors, and rinse repeatedly with sterile PBS until colorless.
[0056] 4. Use sterile scissors to cut the tissue blocks into small pieces until there are no large particles of tissue, add 8 mL of sterile PBS to wash, let it stand for 1 minute, and use a pipette to discard the suspension mixed with red blood cells and tissue fragments.
[0057] 5. Add 0.25% trypsin at 3 to 5 times the volume of the tissue block, place it in a 37°C water bath for digestion for 15 minutes, and shake it continuously during the digestion. When the tissue turns white and loose, add FBS with a final concentration of 10% to terminate the digestion, and repeatedly blow the cells to disperse them into single cells.
[0058] 6. After filtering the cell suspension with sterile gauze, add the filtrate into a centrifuge tube, centrifuge at 1000r / min at room temperature for 8 minutes, and discard the supernatant.
[0059] 7. Resuspend the cells in DMEM medium containing 10% FBS, dilute to an appropriate concentration, add to the cell culture flask, and culture in a 37°C, 5% CO2 incubator until the cells grow into a monolayer of cells and reach 80% abundance.
[0060] 8. Remove the virus from liquid nitrogen and dilute it with culture medium.
[0061] 9. Add the virus to the monolayer of CEF cells.
[0062] CCK-8 method was used to detect the cytotoxicity of taraxasterol and ferulic acid on CEF:
[0063] 1. Treatment of CEF cells with taraxasterol and ferulic acid: 20,000 CEF cells were plated in each well of a 96-well plate, taraxasterol or ferulic acid was diluted into a concentration gradient with culture medium, and the culture medium containing the concentration gradient of taraxasterol or ferulic acid was added to the 96-well plate, with a volume of 100 μL per well, and cultured in a 37°C, 5% CO2 incubator for 72 h.
[0064] 2. The CCK-8 method was used to detect cell viability. The specific operation was as follows: 10 μL of CCK-8 solution was added to each well of the above 96-well plate, and then the culture plate was placed in a 37°C, 5% CO2 incubator for incubation for 3 hours. The absorbance value (OD value) at a wavelength of 450nm was measured with an enzyme marker, and the OD value of each parallel well was averaged. Cell viability % = (OD450 of drug-treated cells - OD450 of blank cells) / (OD450 of control cells - OD450 of blank cells) × 100%. The experiment was repeated three times. The safe concentration of taraxasterol and ferulic acid for CEF cells was determined to be no less than 95% of the group without drug treatment. The results are as follows Figure 3 , the cell viability of 370μM taraxasterol and 320μM ferulic acid treated alone was above 95%, but when used in combination at this concentration, the cell viability was less than 95%, while the cell viability of 350μM taraxasterol and 300μM ferulic acid was above 95% whether used alone or in combination. Therefore, the safe concentration of taraxasterol for CEF cells is <350μM, and the safe concentration of ferulic acid for CEF cells is <300μM.
[0065] Taraxasterol and ferulic acid inhibit MDV replication alone or in combination at the CEF cell level:
[0066] 1. Morphological observation, specifically: 200,000 cells were plated in each well of a 6-well plate. After the cells adhered to the wall and grew into a monolayer, the culture medium was replaced with a culture medium containing an equal volume of DMSO, 3 μM taraxasterol, and 6 μM ferulic acid, respectively or together, and 200 PFU of virus was inoculated into each well. After three days, the CPE caused by MDV was observed under a microscope. Figure 4 As shown, the CPE area was recorded and graphed using Graph Pad Prism 10, with the abscissa being the drug concentration and the ordinate being the CPE area, as shown Figure 5 As shown, the experiment was repeated three times. The results showed that compared with the control group, the CPE area on CEF cells was significantly reduced by taraxasterol and ferulic acid alone or in combination (the taraxasterol group decreased by 65.85%, the ferulic acid group decreased by 72.82%, and the combined treatment decreased by 95.30%). The software CompuSyn (v1.0.1) was used to analyze the Combination Index (CI), and it was found that under the condition of a molar concentration ratio of taraxasterol: ferulic acid = 1:2, the combined treatment had the best effect, which was better than the single treatment, and was a synergistic effect (CI <0.3). Taraxasterol and ferulic acid alone or in combination can inhibit the formation of MDV-induced CEF cell lesions, and the combined treatment effect is better than the single treatment.
[0067] 2. Copy number changes
[0068] a. Drawing of standard curve
[0069] According to the MDV049 gene sequence in the MDV genome (GenBank#AF243438.1), a fluorescence quantitative PCR standard plasmid, pM18T-MDV049 (500) (containing the nucleic acid sequence of the N-terminal 500 amino acids of the MDV049 gene sequence), was constructed, and a pair of real-time fluorescence quantitative PCR primers were designed based on the standard plasmid sequence, the upstream primer is shown in Seq ID NO: 1, and the downstream primer is shown in Seq ID NO: 2. By performing Q-PCR on the standard plasmid, a standard curve with a good linear relationship was drawn using the CT value and the standard plasmid copy number, and the experiment was repeated three times.
[0070] b. Determination of viral copy number
[0071] 200,000 cells were plated in each well of a 6-well plate. After the cells adhered to the wall and grew into a monolayer, the culture medium was replaced with a culture medium containing an equal volume of DMSO, 3 μM taraxasterol, and 6 μM ferulic acid, either alone or together, and 200 PFU were inoculated into each well. The genome was extracted from each well. Q-PCR was performed using the above primers. Quantitative analysis was performed based on the results. The CT values obtained for each group were substituted into the standard curve to obtain the copy number. Graph Pad Prism 10 was used to draw a graph. The horizontal axis is the drug concentration, and the vertical axis is the copy number. Figure 6 As shown. The experiment was repeated three times. The results showed that compared with the control group, the number of MDV copies in CEF cells was significantly reduced by taraxasterol and ferulic acid alone or in combination (the taraxasterol group decreased by 41.07%, the ferulic acid group decreased by 45.00%, and the combined treatment decreased by 85.21%). This shows that taraxasterol and ferulic acid alone or in combination can inhibit the replication of MDV in CEF cells, and the combined treatment effect is better than that of single treatment.
[0072] c. Evaluation of combined medication
[0073] The above CPE area and MDV copy number changes corresponded to the corresponding single and combined drug concentrations. The software CompuSyn (v1.0.1) was used to analyze the Combination Index (CI). It was found that when the molar concentration ratio of taraxasterol: ferulic acid was 1:2, the combined drug effect was the best, and the effect was better than that of single drug use, which was a synergistic inhibitory effect (CI = 0.239).
[0074] Example 4
[0075] Taraxasterol and ferulic acid alone or in combination inhibited MDV replication and the occurrence of MD in the chicken MD disease model:
[0076] The specific operation is as follows: 1-day-old SPF chickens were taken, and the MDV titer was 200 PFU. The challenge method was intraperitoneal inoculation. These challenged chickens were given intraperitoneal injections of taraxasterol, ferulic acid, and combined medications every day. The experimental group was given an effective dose of medication (Table 1), and the group that was not treated with medication and only injected with an equal amount of saline was used as the control group. There were 5 chickens in each group. Blood was collected from the blood vessels under the wings 20 days after the challenge, and T lymphocytes were isolated. The MDV gene copy number was quantitatively analyzed based on the number of 200,000 cells, such as Figure 7 The incidence of MD in each group of chickens within 50 days after infection was calculated. Figure 8 50 days after infection or when the animals were close to death during this period, autopsy was performed and the number of visceral tumors was recorded. The number of tumors in the liver and spleen was counted and plotted. Fig. 9Compared with the control group, the incidence of MD in MDV-challenged chickens decreased significantly with the increase in the dosage, and even no significant symptoms were observed in the combined drug group (the taraxasterol group decreased by 39.39%, the ferulic acid group decreased by 43.43%, and the combined drug group decreased by 78.79%); the number of MDV genome copies in T cells decreased significantly (the taraxasterol group decreased by 60.00%, the ferulic acid group decreased by 48.75%, and the combined drug group decreased by 86.25%); the number of visceral tumors decreased significantly (the taraxasterol group decreased by 56.18%, the ferulic acid group decreased by 53.93%, and the combined drug group decreased by 86.52%), and no significant tumors appeared in some individuals in the combined drug group. This shows that taraxasterol and ferulic acid alone and in combination can inhibit the replication of MDV in chickens and inhibit the occurrence of MD in chickens.
[0077] Example 5
[0078] The taraxasterol and ferulic acid were used alone or in combination by oral, intraperitoneal and intramuscular injection in the chicken MD disease model. In the effective dosage range of Table 1, the experiment showed that the three administration methods can effectively inhibit the replication of MDV in chickens and inhibit the occurrence of chicken MD. In the same dosage range as the single drug, taraxasterol and ferulic acid were combined in different proportions to analyze the anti-MDV and MD effects. The software CompuSyn (v1.0.1) was used to analyze the combination index (CI). It was found that under the condition of the dosage ratio of taraxasterol: ferulic acid = 1:2, the combination effect was the best, and the effect was better than the single drug, which was a synergistic effect (CI <0.7). Table 1 shows the safety range, effective range and optimal dose of taraxasterol and ferulic acid alone and in combination in the three administration methods and cell level experiments. Table 2 shows the effects of the three administration methods and combined drugs.
[0079] Table 1:
[0080]
[0081] Table 2:
[0082]
[0083] Example 6
[0084] Example 6 The CI analysis was used to compare the effects of single medication or the synergistic effects of combined medication. The CI value calculation and analysis showed (as shown in Table 3) that within the effective range of taraxasterol and ferulic acid, the taraxasterol: ferulic acid molar concentration ratio at the cell level was 1:2, which had the best effect on inhibiting CPE, and the taraxasterol: ferulic acid dosage ratio at the animal level was 1:2, which had the best effect on anti-MD and inhibiting MDV replication.
[0085] Table 3:
[0086]
[0087]
[0088] Example 7
[0089] Verify the specific inhibitory effect of taraxasterol on MDV049 protease and the specific inhibitory effect of ferulic acid on US3 protein kinase. The experiment showed that taraxasterol and ferulic acid had no inhibitory effect on chicken USP1, USP7, USP8, USP2, USP5, USP10, USP13, USP15, USP16, USP20, USP33, USP18, USP19, USP28, USP37, USP46, USP47, USP51, CYLD, UCH-L1, UCH-L5, OTU1, OTU4, OTU7 and other proteases, and had no inhibitory effect on chicken protein kinase (>114μM).
[0090] The experimental method is the same as the MDV049 protease and US3 protein kinase inhibition experiment. Chicken PKB, PKA, MAPK, CDK4, USP1, USP7, USP8 and other enzymes use 1-3nM enzyme concentration, and the inhibitor concentration >114μM has no significant inhibitory effect on the above enzyme activities.
[0091] References: Experimental methods and identification standards: Chen, J., et al., Selective and cell-active inhibitors of the USP1 / UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol, 2011. 18(11): p. 1390-400.
[0092] Example 8
[0093] The present invention screens MDV049 protease and US3 protein kinase inhibitors.
[0094] We use all of the more than 5,000 protease inhibitors and protein kinase inhibitors included in Topscience and MedChemExpress for high-throughput screening. Among them are human USP1 inhibitors ML-323 (Cas No.1572414-83-5), PR-619 (Cas No.2645-32-1), SJB3-019A (Catalog No.B1307), Pimozide (Cas No.2062-78-4), GW7647 (Cas No.265129-71-3), Flupenthixol (Cas No.51529-01-2), Trifluoperazine (Cas No.440-17-5), Rottlerin (Cas No.82-08-6), and USP7 / 8 inhibitors HBX19818 (Cas No.1426944-49-1), P22077 (Cas No.1247819-59-5), GNE-6640 (Cas No.2009273-67-8), GNE-6776 (Cas No.2009273-71-4), NSC 632839 (Cas No.157654-67-6), BAY 11-7082 (CasNo.19542-67-7), USP7-IN-1 (Cas No.1381291-36-6), C598-0466 (Catalog No.A8740), NSC632839 (Cas No.157654-67-6) had no inhibitory effect on MDV049 protease (>114μM). Protein kinase inhibitors PF-04979064, MLi-2, UKI-1, BFH772, CAN508, PD-161570, WYE-132, AEE788, etc. had no inhibitory effect on US3 protein kinase encoded by MDV (>114μM).
[0095] Example 9
[0096] The optimal doses of taraxasterol and ferulic acid under various administration methods in Table 1 were used to administer to healthy chickens to prevent Marek's disease. The results showed that taraxasterol and ferulic acid alone and in combination as preventive drugs for Marek's disease effectively reduced the infection rate of MDV in chickens and the incidence of MD. It also proved that oral administration, intramuscular injection, and intraperitoneal injection are all effective administration methods for prevention.
[0097] The above results can be verified by infecting chickens with MDV after preventive medication, and then detecting the chicken MDV infection rate and MD incidence rate, as well as the virus level in the body.
[0098] In the present invention, taraxasterol is used as an inhibitor of MDV049 protease, and ferulic acid is used as an inhibitor of US3 protein kinase, and they are mainly antiviral in the treatment of Marek's disease, that is, the treatment time for Marek's disease is the stage when the virus is infected but no tumor occurs, and the enzyme activities of MDV049 protease and US3 protein kinase are used to inhibit viral replication and the generation of tumor cells, thereby playing a therapeutic role.
[0099] The above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. Use of taraxasterol or ferulic acid or taraxasterol and ferulic acid in combination in the preparation of a drug for preventing or treating Marek's disease, characterized in that: The concentration of taraxasterol at the cellular level is 0.5 to 350 μM; or the concentration of ferulic acid at the cellular level is 3 to 300 μM; or a combination of 0.5 to 350 μM taraxasterol and 3 to 300 μM ferulic acid, and within the concentration range of the combined use, the molar concentration ratio of taraxasterol to ferulic acid is 2:1-1:
8.
2. Use of taraxasterol or ferulic acid or a combination of taraxasterol and ferulic acid in the preparation of a drug for inhibiting tumor formation in chickens with Marek's disease, characterized in that: The concentration of taraxasterol at the cellular level is 0.5 to 350 μM; or the concentration of ferulic acid at the cellular level is 3 to 300 μM; or a combination of 0.5 to 350 μM taraxasterol and 3 to 300 μM ferulic acid, and within the concentration range of the combined use, the molar concentration ratio of taraxasterol to ferulic acid is 2:1-1:
8.
3. Use of taraxasterol or ferulic acid or a combination of taraxasterol and ferulic acid in the preparation of a drug for inhibiting the replication of Marek's disease virus in vivo or in vitro culture system, characterized in that: The concentration of taraxasterol at the cellular level is 0.5 to 350 μM; or the concentration of ferulic acid at the cellular level is 3 to 300 μM; or a combination of 0.5 to 350 μM taraxasterol and 3 to 300 μM ferulic acid, and within the concentration range of the combined use, the molar concentration ratio of taraxasterol to ferulic acid is 2:1-1:8.
Citation Information
Patent Citations
Preparation method of phytosterol / stanol ferulate
CN111995653A
Preparation method of dandelion extract, dandelion extract and application of dandelion extract
CN112656734A
Medicine for inhibiting Marek's disease virus replication and preventing or resisting Marek's disease
CN112972476A
